JP7781519B2 - グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 - Google Patents

グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法

Info

Publication number
JP7781519B2
JP7781519B2 JP2020511375A JP2020511375A JP7781519B2 JP 7781519 B2 JP7781519 B2 JP 7781519B2 JP 2020511375 A JP2020511375 A JP 2020511375A JP 2020511375 A JP2020511375 A JP 2020511375A JP 7781519 B2 JP7781519 B2 JP 7781519B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
gcgr
hyperammonemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020511375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531532A5 (https=
JP2020531532A (ja
Inventor
はるか 岡本
シャイピン チェン
ジェスパー グロマダ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2020531532A publication Critical patent/JP2020531532A/ja
Publication of JP2020531532A5 publication Critical patent/JP2020531532A5/ja
Priority to JP2023169177A priority Critical patent/JP2023182691A/ja
Application granted granted Critical
Publication of JP7781519B2 publication Critical patent/JP7781519B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2020511375A 2017-08-22 2018-08-21 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 Active JP7781519B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023169177A JP2023182691A (ja) 2017-08-22 2023-09-29 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762548632P 2017-08-22 2017-08-22
US62/548,632 2017-08-22
PCT/US2018/047286 WO2019040471A1 (en) 2017-08-22 2018-08-21 METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023169177A Division JP2023182691A (ja) 2017-08-22 2023-09-29 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法

Publications (3)

Publication Number Publication Date
JP2020531532A JP2020531532A (ja) 2020-11-05
JP2020531532A5 JP2020531532A5 (https=) 2021-09-30
JP7781519B2 true JP7781519B2 (ja) 2025-12-08

Family

ID=63638351

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511375A Active JP7781519B2 (ja) 2017-08-22 2018-08-21 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法
JP2023169177A Pending JP2023182691A (ja) 2017-08-22 2023-09-29 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023169177A Pending JP2023182691A (ja) 2017-08-22 2023-09-29 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法

Country Status (6)

Country Link
US (2) US12139546B2 (https=)
EP (1) EP3672620A1 (https=)
JP (2) JP7781519B2 (https=)
CA (1) CA3071387A1 (https=)
MX (2) MX2020002057A (https=)
WO (1) WO2019040471A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210642A1 (en) * 2019-04-10 2020-10-15 Camp4 Therapeutics Corporation Methods and compositions for treating urea cycle disorders
CA3205005A1 (en) * 2020-12-16 2022-06-23 Rush University Medical Center Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders
MX2024007790A (es) * 2021-12-22 2024-09-06 Camp4 Therapeutics Corp Modulación de la transcripción génica utilizando oligonucleótidos antisentido dirigidos a arn reguladores.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501512A (ja) 2010-11-23 2014-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体に対するヒト抗体
JP2014532179A (ja) 2011-09-30 2014-12-04 ハイペリオン セラピューティクス，インコーポレイテッド 窒素捕集薬の治療監視の方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5836308B2 (ja) 1977-02-10 1983-08-08 大塚製薬株式会社 抗体の製造方法
US4206199A (en) 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives
JPS56163456A (en) 1980-05-21 1981-12-16 Otsuka Pharmaceut Co Ltd Preparation of antigen
US4423034A (en) 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0658200B1 (en) 1992-08-28 2004-12-22 Novo Nordisk A/S Glucagon receptors
JP2729159B2 (ja) 1994-10-31 1998-03-18 日清製粉株式会社 ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
CA2547785A1 (en) 2003-12-19 2005-07-21 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
DE602005006806D1 (de) 2004-06-04 2008-06-26 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
AU2005272043B2 (en) 2004-07-07 2010-07-29 Merck Sharp & Dohme Corp. Pyrazole amide derivatives, compositions containing such compounds and methods of use
US7625938B2 (en) 2004-07-22 2009-12-01 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
SI1856090T1 (sl) 2005-02-11 2010-02-26 Lilly Co Eli Substituirani derivati tiofena kot antagonisti glukagonskega receptorja, priprava in terapevtske uporabe
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
US7803951B2 (en) 2005-03-30 2010-09-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
AR056574A1 (es) 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
CA2649751A1 (en) 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compound/glucagon antibody compositions
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
KR20190126460A (ko) 2007-02-09 2019-11-11 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
CL2009000586A1 (es) 2008-03-27 2010-06-04 Lilly Co Eli Fragmento fab o anticuerpo monoclonal humanizado que lo comprende que se une a receptor de glucagon humano/glucr, de rata, de raton, y mono cinomolgus; vector que comprende polinuccleotido codificante; celula huesped que lo comprende; composicion farmaceutica; uso para tratar diabetes tipo 1 o 2, o para la perdida de peso
EP2291358B1 (en) 2008-05-16 2018-03-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonists, compositions, and methods for their use
EP2346830B1 (en) 2008-09-15 2015-05-13 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010071750A1 (en) 2008-12-19 2010-06-24 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds
US20110281795A1 (en) 2009-01-28 2011-11-17 Songnian Lin Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8324384B2 (en) 2009-02-12 2012-12-04 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8809579B2 (en) 2009-02-13 2014-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2012188352A (ja) 2009-07-13 2012-10-04 Dainippon Sumitomo Pharma Co Ltd ３−（４−置換アルキル−フェニル）−２−フランカルボン酸誘導体およびその薬学的に許容される塩
FR2959129B1 (fr) * 2010-04-21 2013-02-01 Lucane Pharma Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations
US9453073B2 (en) 2011-12-02 2016-09-27 Eli Lilly And Company Anti-glucagon antibodies and uses thereof
KR20170062466A (ko) 2014-09-16 2017-06-07 리제너론 파마슈티칼스 인코포레이티드 항-글루카곤 항체 및 그것의 사용

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501512A (ja) 2010-11-23 2014-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体に対するヒト抗体
JP2014532179A (ja) 2011-09-30 2014-12-04 ハイペリオン セラピューティクス，インコーポレイテッド 窒素捕集薬の治療監視の方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Gastroenterology, 1985年, 発行日, Vol.88, pp.750-756
Ｎｅｏｎａｔａｌ Ｃａｒｅ, 2012年, 発行日, 25(11), 1205-1210
Scandinavian Journal of Gastroenterology, 1990年, 発行日, Vol.25, Supplement 176, p.14

Also Published As

Publication number Publication date
EP3672620A1 (en) 2020-07-01
MX2020002057A (es) 2020-07-13
WO2019040471A1 (en) 2019-02-28
JP2023182691A (ja) 2023-12-26
US12139546B2 (en) 2024-11-12
MX2024011106A (es) 2024-09-18
JP2020531532A (ja) 2020-11-05
WO2019040471A9 (en) 2019-03-21
US20250101119A1 (en) 2025-03-27
CA3071387A1 (en) 2019-02-28
US20210130480A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
CN103930444B (zh) 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
JP6375113B2 (ja) 被験者の特定のグループを処置する方法において使用するためのｐｃｓｋ９に対するヒト抗体
JP7633213B2 (ja) グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法
US10513557B2 (en) Anti-ASIC1 antibodies and uses thereof
US20140099312A1 (en) Methods for Treating Hypercholesterolemia and Reducing LDL-C Using Antibodies to PCSK9
US20250101119A1 (en) Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
JP2012511913A (ja) Ｐｃｓｋ９に対する高親和性ヒト抗体
CN109069868B (zh) 通过施用与angptl3抑制剂组合的pcsk9抑制剂治疗高脂血症患者的方法
KR20120104613A (ko) 사람 안지오포이에틴-유사 단백질 4에 대한 사람 항체
HK40114568A (zh) 通过干扰胰高血糖素受体的信号传导治疗重度胰岛素抵抗的方法
HK40006818A (en) Anti-asic1 antibodies and uses thereof
BR112014018651B1 (pt) Anticorpos anti-asic1, e composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200422

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230929

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231005

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251126

R150 Certificate of patent or registration of utility model

Ref document number: 7781519

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150